Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD )

0.8787 +0.1042 (+13.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
As the stock market corrects, focusing on stable investments is crucial. This is why you should steer clear of these biotech stocks to avoid. 
Via InvestorPlace
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
The biotech industry offers investors unique investment opportunities but these three are biotechs to sell. 
Via InvestorPlace
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks Mixed, Headed For Monthly Wins
In what appears to be a theme this week, stocks are hesitant midday as investors unpack this morning's jobs and inflation data. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?
Ironwood Pharmaceuticals' SBS-IF treatment Apraglutide's Phase 3 trial met primary endpoints, reducing PS dependency by 25.5% vs. placebo, but misses on two key secondary endpoints. 
Via Benzinga
Nasdaq Gains 100 Points Following PCE Data
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the... 
Via Benzinga
Topics Stocks
Exposures US Equities
PSNY Stock Alert: Polestar Makes Moves With Its Joint Venture
Polestar stock is rising higher on Thursday as holders of PSNY shares react to an update for the company's Chinese joint venture. 
Via InvestorPlace
Ironwood Pharmaceuticals Ran Up 32% Over Two Months — And Just Lost It All
The company still plans to ask for approval of its short bowel syndrome treatment. 
Via Investor's Business Daily
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&P 500, and small caps. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?
Ironwood Pharmaceuticals stock is falling on Thursday with investors in IRWD unimpressed by its latest Phase III clinical trial results. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning! 
Via InvestorPlace
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Top 4 Health Care Stocks You May Want To Dump In February
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.